Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Sells 2,403 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone sold 2,403 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $138.41, for a total transaction of $332,599.23. Following the transaction, the chief marketing officer now owns 79,621 shares of the company’s stock, valued at approximately $11,020,342.61. The trade was a 2.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Robert Iannone also recently made the following trade(s):

• On Friday, March 7th, Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00.

Jazz Pharmaceuticals Trading Up 1.4 %

JAZZ stock opened at $137.96 on Friday. The business has a fifty day moving average price of $129.52 and a 200 day moving average price of $120.76. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The stock has a market capitalization of $8.38 billion, a price-to-earnings ratio of 19.43, a P/E/G ratio of 1.04 and a beta of 0.44.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on JAZZ shares. Barclays reissued an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Morgan Stanley restated an “overweight” rating and set a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. HC Wainwright raised their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Royal Bank of Canada lowered their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Finally, Piper Sandler restated an “overweight” rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $190.53.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bessemer Group Inc. grew its holdings in Jazz Pharmaceuticals by 0.3% during the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock worth $3,317,000 after acquiring an additional 92 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 97 shares during the last quarter. Synovus Financial Corp increased its holdings in shares of Jazz Pharmaceuticals by 0.5% in the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock valued at $2,365,000 after purchasing an additional 100 shares in the last quarter. Quarry LP raised its position in Jazz Pharmaceuticals by 6.3% in the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $209,000 after purchasing an additional 100 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 101 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.